Switch theme
Sign up to access all valuation multiples
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
2001
15
Last FY Revenue $1.2M
Last FY EBITDA -$5.9M
$33.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Intervacc achieved revenue of $1.2M and an EBITDA of -$5.9M.
Intervacc expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Intervacc valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.2M | XXX | XXX | XXX |
| Gross Profit | XXX | -$0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | -30% | XXX | XXX | XXX |
| EBITDA | XXX | -$5.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -482% | XXX | XXX | XXX |
| EBIT | XXX | -$8.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | -656% | XXX | XXX | XXX |
| Net Profit | XXX | -$7.8M | XXX | XXX | XXX |
| Net Margin | XXX | -641% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Intervacc's stock price is SEK 1 (or $0).
Intervacc has current market cap of SEK 355M (or $36.6M), and EV of SEK 321M (or $33.1M).
See Intervacc trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33.1M | $36.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Intervacc has market cap of $36.6M and EV of $33.1M.
Intervacc's trades at 27.2x EV/Revenue multiple, and -5.6x EV/EBITDA.
Equity research analysts estimate Intervacc's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Intervacc's P/E ratio is not available.
See valuation multiples for Intervacc and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.6M | XXX | $36.6M | XXX | XXX | XXX |
| EV (current) | $33.1M | XXX | $33.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 27.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -4.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -4.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIntervacc's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Intervacc's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Intervacc's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Intervacc and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -482% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 626% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intervacc acquired XXX companies to date.
Last acquisition by Intervacc was XXXXXXXX, XXXXX XXXXX XXXXXX . Intervacc acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Intervacc founded? | Intervacc was founded in 2001. |
| Where is Intervacc headquartered? | Intervacc is headquartered in Sweden. |
| How many employees does Intervacc have? | As of today, Intervacc has 15 employees. |
| Is Intervacc publicy listed? | Yes, Intervacc is a public company listed on STO. |
| What is the stock symbol of Intervacc? | Intervacc trades under IVACC ticker. |
| When did Intervacc go public? | Intervacc went public in 2017. |
| Who are competitors of Intervacc? | Similar companies to Intervacc include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Intervacc? | Intervacc's current market cap is $36.6M |
| Is Intervacc profitable? | Yes, Intervacc is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
